The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-07. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Existential – Existential psychotherapy postulates that people are largely free to choose who we are and how we interpret and interact with the world. It intends to help the client find deeper meaning in life and to accept responsibility for living. As such, it addresses fundamental issues of life, such as death, aloneness, and freedom. The therapist emphasizes the client's ability to be self-aware, freely make choices in the present, establish personal identity and social relationships, create meaning, and cope with the natural anxiety of living. Gestalt – Gestalt therapy was primarily founded by Fritz Perls in the 1950s. This therapy is perhaps best known for using techniques designed to increase self-awareness, the best-known perhaps being the "empty chair technique". Such techniques are intended to explore resistance to "authentic contact", resolve internal conflicts, and help the client complete "unfinished business". Postmodern – Postmodern psychology says that the experience of reality is a subjective construction built upon language, social context, and history, with no essential truths. Since "mental illness" and "mental health" are not recognized as objective, definable realities, the postmodern psychologist instead sees the goal of therapy strictly as something constructed by the client and therapist. Forms of postmodern psychotherapy include narrative therapy, solution-focused therapy, and coherence therapy. Transpersonal – The transpersonal perspective places a stronger focus on the spiritual facet of human experience.
==== Optical peptide biosensors ==== In optical peptide biosensors, peptide-analyte binding events is converted into measurable optical changes. This depends on changes in fluorescence, luminescence, or absorbance upon analyte binding. The peptide sequence may be fluorescently labeled or monitored label-free through shifts in refractive index or optical density.
=== Legal status === Oxycodone is subject to international conventions on narcotic drugs. In addition, oxycodone is subject to national laws that differ by country. The 1931 Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs of the League of Nations included oxycodone. The 1961 Single Convention on Narcotic Drugs of the United Nations, which replaced the 1931 convention, categorized oxycodone in Schedule I. Global restrictions on Schedule I drugs include "limit[ing] exclusively to medical and scientific purposes the production, manufacture, export, import, distribution of, trade in, use and possession of" these drugs; "requir[ing] medical prescriptions for the supply or dispensation of [these] drugs to individuals"; and "prevent[ing] the accumulation" of quantities of these drugs "in excess of those required for the normal conduct of business".
Sources: en.wikipedia.org
=== Museums === Five Museums in Le Havre have the distinction of being classified as Musées de France (Museums of France) an official label granted only to museums of a high status. The five museums are:
Transformation of a bacterial host with two different plasmids is required. One is designed to express a DNA-binding protein-of-interest as a fusion construct with a subunit of RNA polymerase (bait). The other plasmid contains a region of randomized sequence representing potential binding sites (prey) which, if bound to by the chimeric fusion product, drives expression of downstream reporter genes. This reporter region facilitates both positive and negative selection by HIS3 and URA3, respectively, which together allow for isolation of the prey containing the true DNA target sequence. HIS3 and URA3 encode proteins required for biosynthesis of histidine and uracil. Using a negative selectable marker is crucial for greatly reducing the incidence of false-positives. Self-activating prey, where the randomized region facilitate reporter expression in the absence of TF binding, are removed by transforming the reporter vector library into bacteria in the absence of bait and assaying for growth on plates containing 5-fluoro-orotic acid (5-FOA). The protein product of URA3 converts 5-FOA into a toxic compound, thereby allowing survival of only those colonies that contain reporter vectors which are not self-activating. Negative selection normally precedes positive selection so that a smaller, purified prey library can be subjected to the more rigorous positive selection process. Upon transformation of the purified prey library with the bait plasmid, positive selection is achieved by growing the host E.
== Prevention == Preventing recurrence of hyperkalemia typically involves reduction of dietary potassium, removal of an offending medication, and/or the addition of a diuretic (such as furosemide or hydrochlorothiazide). Sodium polystyrene sulfonate and sorbitol (combined as Kayexalate) are occasionally used on an ongoing basis to maintain lower serum levels of potassium, though the safety of long-term use of sodium polystyrene sulfonate for this purpose is not well understood. High dietary sources include meat, chicken, seafood, vegetables such as avocados, tomatoes and potatoes, fruits such as bananas, oranges and nuts.
Sources: en.wikipedia.org
== Interactions == Tavapadon is substrate for CYP3A4 and hence interacts with CYP3A4 inhibitors and inducers. In addition to being a CYP3A4 substrate, tavapadon is a CYP3A4 inducer and can interact with CYP3A4 substrates. It is also a CYP2C8 inhibitor and can interact with CYP2C8 substrates. Tavapadon is a BCRP inhibitor and can interact with substrates of this protein as well.
Block copolymers are made up of blocks of different polymerized monomers. For example, polystyrene-b-poly(methyl methacrylate) or PS-b-PMMA (where b = block) is usually made by first polymerizing styrene, and then subsequently polymerizing methyl methacrylate (MMA) from the reactive end of the polystyrene chains. This polymer is a "diblock copolymer" because it contains two different chemical blocks. Triblocks, tetrablocks, multiblocks, etc. can also be made. Diblock copolymers are made using living polymerization techniques, such as atom transfer free radical polymerization (ATRP), reversible addition fragmentation chain transfer (RAFT), ring-opening metathesis polymerization (ROMP), and living cationic or living anionic polymerizations. An emerging technique is chain shuttling polymerization. The synthesis of block copolymers requires that both reactivity ratios are much larger than unity (r1 >> 1, r2 >> 1) under the reaction conditions, so that the terminal monomer unit of a growing chain tends to add a similar unit most of the time. The "blockiness" of a copolymer is a measure of the adjacency of comonomers vs their statistical distribution. Many or even most synthetic polymers are in fact copolymers, containing about 1-20% of a minority monomer. In such cases, blockiness is undesirable. A block index has been proposed as a quantitative measure of blockiness or deviation from random monomer composition.
Bain de Soleil was an American brand of sunscreen that was produced by Bayer. The brand was known for low-SPF products that were typically marketed to women seeking skin tanning. It was affiliated with the Coppertone brand. The name Bain de Soleil is French for "sun bathing." The brand used the slogan "Welcome to a place more colorful." In the 1970s and 1980s, the brand used the slogan (especially featured in television commercials) "Bain de Soleil, for the St. Tropez tan." The brand was discontinued in December 2019.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.